Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children

被引:59
作者
Ashkenazi, S
Passwell, JH
Harlev, E
Miron, D
Dagan, R
Farzan, N
Ramon, R
Majadly, F
Bryla, DA
Karpas, AB
Robbins, JB
Schneerson, R
机构
[1] Schneider Childrens Med Ctr Israel, Felsenstein Res Ctr, Petah Tiqwa, Israel
[2] Haemek Med Ctr, Chaim Sheba Med Ctr, Dept Pediat, Samuel Jared Kushnick Pediat Immunol Lab, Afula, Israel
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Pediat Infect Dis Unit, Beer Sheva, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[5] NICHHD, NIH, Bethesda, MD 20892 USA
[6] Hadassah Med Ctr, IL-91120 Jerusalem, Israel
[7] Carmel Med Ctr, Haifa, Israel
[8] Community Clin, Daliat El Carmel, Israel
[9] Community Clin, Petah Tiqwa, Israel
[10] Community Clin, Kibbutz Yagur, Israel
[11] Community Clin, Kibbutz Hulda, Israel
[12] Community Clin, Kibbutz Givat Hayim, Israel
[13] Community Clin, Kibbutz Ein Hahoresh, Israel
关键词
D O I
10.1086/314759
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
O-specific polysaccharide conjugates of shigellae were safe and immunogenic in young adults, and a Shigella sonnei conjugate conferred protection [1-3], Shigellosis is primarily a disease of children; therefore, the safety and immunogenicity of S. sonnei and Shigella flexneri 2a conjugates were studied in 4- to 7-year-old children. Local and systemic reactions were minimal. The first injection of both conjugates elicited significant rises in geometric mean levels of serum IgG only to the homologous lipopolysaccharide (LPS) (S, sonnei, 0.32-8.25 ELISA units [EU]; S. flexneri 2a, 1.15-20.5 EU; P < .0001), Revaccination at 6 weeks induced a booster response to S. flexneri 2a LPS (20.5-30.5 EU, P = .003). Six months later, the geometric mean levels of Ige anti-LPS for both groups were higher than the prevaccination levels (P < .0001). Similar, but lesser, rises were observed for IgM and IgA anti-LPS, The investigational Shigella conjugates were safe and immunogenic in children and merit evaluation of their efficacy.
引用
收藏
页码:1565 / 1568
页数:4
相关论文
共 15 条
[1]
INCREASING ANTIMICROBIAL RESISTANCE OF SHIGELLA ISOLATES IN ISRAEL DURING THE PERIOD 1984 TO 1992 [J].
ASHKENAZI, S ;
MAYZAHAV, M ;
SULKES, J ;
ZILBERBERG, R ;
SAMRA, Z .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :819-823
[2]
RECENT TRENDS IN THE EPIDEMIOLOGY OF SHIGELLA SPECIES IN ISRAEL [J].
ASHKENAZI, S ;
MAYZAHAV, M ;
DINARI, G ;
GABBAY, U ;
ZILBERBERG, R ;
SAMRA, Z .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (05) :897-899
[3]
ASHKENAZI S, 1994, ISRAEL J MED SCI, V30, P495
[4]
BLACK RE, 1984, PEDIATRICS, V73, P799
[5]
SERUM ANTIBODIES TO LIPOPOLYSACCHARIDE AND NATURAL IMMUNITY TO SHIGELLOSIS IN AN ISRAELI MILITARY POPULATION [J].
COHEN, D ;
GREEN, MS ;
BLOCK, C ;
ROUACH, T ;
OFEK, I .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (05) :1068-1071
[6]
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults [J].
Cohen, D ;
Ashkenazi, S ;
Green, MS ;
Gdalevich, M ;
Robin, G ;
Slepon, R ;
Yavzori, M ;
Orr, N ;
Block, C ;
Ashkenazi, I ;
Shemer, J ;
Taylor, DN ;
Hale, TL ;
Sadoff, JC ;
Pavliakova, D ;
Schneerson, R ;
Robbins, JB .
LANCET, 1997, 349 (9046) :155-159
[7]
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers [J].
Cohen, D ;
Ashkenazi, S ;
Green, M ;
Lerman, Y ;
Slepon, R ;
Robin, G ;
Orr, N ;
Taylor, DN ;
Sadoff, JC ;
Chu, CY ;
Shiloach, J ;
Schneerson, R ;
Robbins, JB .
INFECTION AND IMMUNITY, 1996, 64 (10) :4074-4077
[8]
GOREN A, 1992, PEDIATRICS, V89, P1189
[9]
SHIGELLA LIPOPOLYSACCHARIDE ANTIBODIES IN PEDIATRIC POPULATIONS [J].
PASSWELL, JH ;
FREIER, S ;
SHOR, R ;
FARZAM, N ;
BLOCK, C ;
LISON, M ;
SHIFF, E ;
ASHKENAZI, S .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (10) :859-865
[10]
PICKERING LK, 1990, SEMIN PEDIATR INFECT, V1, P263